SPD489
SPD489-211
Phase 3 small_molecule completed
Quick answer
SPD489 for Attention Deficit Hyperactivity Disorder (ADHD) is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 2 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Attention Deficit Hyperactivity Disorder (ADHD)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed